AstraZeneca

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

AstraZeneca's vandetanib approved for MTC

Thursday, April 7, 2011 11:35 AM

The FDA has approved AstraZeneca’s vandetanib, which is a kinase inhibitor and has no brand name yet, to treat adult patients with late-stage medullary thyroid cancer (MTC) who are ineligible for surgery and who have disease that is growing or causing symptoms. The once-daily oral treatment is the first agency-approved drug for MTC, which is estimated to represent 3%-5% of all thyroid cancer.

More... »

Neuroscience drug development slows, requires funding

Tuesday, March 29, 2011 11:49 AM

Many European pharmaceutical companies have significantly reduced their workflow in the realm of neuroscience, according to Fierce Biotech. Companies are challenged with a high risk of trial failure while investors demand new products. 

More... »

AstraZeneca drug enters phase III

Friday, March 18, 2011 10:28 AM

AstraZeneca has begun enrollment of a late-stage trial for an investigational opioid-induced constipation treatment licensed from Nektar Therapeutics.

More... »

AstraZeneca joins quest for TB therapies

Monday, March 7, 2011 10:43 AM

AstraZeneca became the newest member of a $22 million multi-member partnership to find new therapies for tuberculosis. The current remedies for the disease have been in use for over 50 years, and require several months or years of treatment. But with the expertise and help of companies including AZ and Sanofi-aventis, and academic partners University of Cambridge and institutions in Pavia, Italy and Uppsala, Sweden, the group hopes to cut treatment time.

More... »

ProPublica report: big pharma paid hundreds of physicians over $100,000 in speaking fees

Monday, November 8, 2010 11:12 AM

Several doctors paid to speak on behalf of big pharmaceutical companies aren’t, in fact, the thought leaders consumers often consider them to be, but instead have been sanctioned for various forms of misconduct. And psychiatrists collect more in speaking and consulting fees from pharma companies than doctors in any other specialty.

More... »

CenterWatch Monthly September 2010

Wednesday, September 1, 2010 11:31 AM

"Sunshine law" puts cloud of concern over sponsors, sites

More... »

CenterWatch Monthly May 2010

Tuesday, May 4, 2010 12:51 PM

Euro Sites Rate Abbott, Boehringer Ingelheim Top Sponsors in 2010

More... »

Quintiles in Alliances with AstraZeneca, Eisai

Wednesday, November 4, 2009 07:21 AM

Quintiles has entered into a strategic alliance with AstraZeneca. The contract research organization (CRO)-clinical pharmacology alliance with AstraZeneca was formed to deliver the sponsor’s clinical pharmacology studies across multiple therapy areas and around the globe.

More... »

AstraZeneca Bets More Chips On China

Wednesday, June 28, 2006 12:03 PM

AstraZeneca is investing $100 million more in China over the next three years to build the AstraZeneca Innovation Centre China, an R&D facility to study the benefits of new drugs to Chinese patients. Already one of the most heavily invested in China among big pharma companies, AstraZeneca is further distinguishing itself as the leader there with this new commitment.

More... »